Centogene (CNTG)
(Delayed Data from NSDQ)
$0.42 USD
+0.02 (5.05%)
Updated May 14, 2024 03:54 PM ET
After-Market: $0.44 +0.02 (4.74%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CNTG 0.42 +0.02(5.05%)
Will CNTG be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CNTG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTG
Patterson Cos. (PDCO) Q4 Earnings and Revenues Top Estimates
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
CNTG: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Lags Revenue Estimates
Tabula Rasa Healthcare (TRHC) Reports Q4 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
Other News for CNTG
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
CENTOGENE and Evotec Unveil Potential Gaucher Disease Treatment
Centogene, Evotec discover new molecule with potential to treat Gaucher disease
Centogene’s Biodatabank Drives Rare Disease Breakthroughs
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients